Cargando…
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
BACKGROUND: Despite the COVID-19 pandemic, there has been considerable activity in the clinical development of novel and improved drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) during 2020. The agents that were investigated can be divided into “symptomatic” (all...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461678/ https://www.ncbi.nlm.nih.gov/pubmed/34151864 http://dx.doi.org/10.3233/JPD-219006 |